Mission Statement, Vision, & Core Values (2026) of Sihuan Pharmaceutical Holdings Group Ltd.

Sihuan Pharmaceutical Holdings Group Ltd., founded in 2001 and listed on the Hong Kong Stock Exchange in 2010, couples a clear mission of 'innovation for human health' with a bold vision to become a competitive international pharmaceutical and medical aesthetics leader, leveraging a research engine of over 1,000 researchers and more than 110 active projects to support a diversified portfolio of over 200 proprietary products across cardiovascular, central nervous system, oncology and diabetes areas; with an R&D investment of approximately RMB 1.1 billion in Q1 2023 and recognition among China's Top 100 Pharmaceutical Innovative Enterprises in 2023, Sihuan's core values-integrity and responsibility, pragmatism and innovation, cooperation and sharing, and pursuit of excellence-drive its strategy, corporate social responsibility and push toward internationalization, so explore how these pillars translate into product pipelines, strategic partnerships and sustainability efforts. }

Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK) - Intro

• Founded: 2001; Hong Kong listing: 2010 (HKEX: 0460.HK).
• Core focus: research, development, manufacturing and sales of pharmaceuticals and medical aesthetic products - principal therapeutic areas include cardiovascular, central nervous system (CNS), oncology and diabetes.
• R&D capacity: over 1,000 researchers and more than 110 active pharmaceutical research projects.
• Product portfolio: a diversified pipeline with over 200 proprietary products, with strong commercial presence in cardiovascular and CNS treatments.
• Recognition: selected among the first echelon of China's Top 100 Pharmaceutical Innovative Enterprises in 2023.
• Corporate social responsibility: ongoing commitments to human health initiatives and environmental sustainability across operations.

• To advance accessible, high-quality medicines and medical aesthetic solutions that improve patient outcomes across major therapeutic areas.
• To drive innovation through sustained R&D investment and strategic collaborations, translating research into therapeutics and commercial products.

• To be a globally respected Chinese pharmaceutical innovator, leading in cardiovascular, CNS, oncology and metabolic disease treatments while expanding international reach.
• To integrate innovation, manufacturing excellence and ethical practices to deliver long-term value for patients, partners and shareholders.

• Patient-first: prioritize safety, efficacy and accessibility in product development and commercialization.
• Innovation-driven: invest in scientific talent and projects to maintain a sustainable pipeline.
• Integrity and compliance: adhere to regulatory, ethical and quality standards in manufacturing and clinical work.
• Sustainability: minimize environmental footprint and support community health programs.
• Collaboration: foster partnerships with academic, clinical and industrial stakeholders to accelerate translation.

• Integrated platform combining discovery research, clinical development and manufacturing scale-up; over 110 active projects span small molecules, biologics and medical aesthetic formulations.
• Talent base: >1,000 researchers concentrated in medicinal chemistry, pharmacology, clinical development and regulatory affairs to shorten time-to-market for key assets.
• Pipeline prioritization emphasizes cardiovascular and CNS candidates while advancing oncology and metabolic disease assets into later-stage trials.

• Over 200 proprietary products marketed through national and regional channels; flagship strength remains in cardiovascular therapeutics and central nervous system agents.
• Sales and distribution leverage both hospital channels for prescription medicines and aesthetic clinics for medical aesthetic products.

• Health initiatives: programs targeting improved access to essential medicines and patient education in cardiovascular and chronic disease management.
• Environmental measures: investments in greener manufacturing processes and waste-reduction initiatives across production sites.
• Governance: ongoing efforts to strengthen compliance, pharmacovigilance and supply‑chain transparency.

Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK) Overview

Mission Statement - 'Innovation for human health.' Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK) centers its corporate mission on developing innovative pharmaceutical solutions to improve global health outcomes, with a strategic emphasis on cardiovascular and central nervous system therapies and an expanding presence in medical aesthetics and biopharmaceuticals.

• R&D commitment: approximately RMB 1.1 billion spent in Q1 2023 on research and development targeting pipeline expansion and lifecycle management of key products.
• Therapeutic focus: cardiovascular, central nervous system, diabetes, oncology, and medical aesthetics.
• Recognition: named among China's Top 100 Pharmaceutical Innovative Enterprises in 2023.
• Strategic target: to become a leading medical aesthetics and biopharmaceutical company in China through sustained innovation and portfolio diversification.

Core Values and Strategic Priorities

• Patient-centered innovation - prioritizing safe, effective therapies that address unmet clinical needs.
• Scientific excellence - investing in R&D and partnerships to accelerate translation from discovery to clinic.
• Quality and compliance - maintaining rigorous manufacturing and regulatory standards for domestic and international supply.
• Sustainable growth - balancing reinvestment in innovation with market expansion in specialty segments such as medical aesthetics.

Key mission-driven metrics and organizational position

Selected strategic initiatives aligned with the mission

• Pipeline acceleration programs for cardiovascular and CNS candidates backed by increased R&D funding.
• Targeted expansion into medical aesthetics through product development and potential M&A or partnerships.
• Quality and regulatory strengthening to support broader domestic and export market access.

Further context and financial perspective are available in the full company financial review: Breaking Down Sihuan Pharmaceutical Holdings Group Ltd. Financial Health: Key Insights for Investors

Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK) - Mission Statement

• Integrating research, development, manufacturing and sales to form an end-to-end value chain that supports faster commercialization.
• Adapting product mix dynamically to market changes, leveraging diversified portfolios across prescription medicines, biologics and medical-aesthetic products.
• Building a modern R&D center and recruiting high-tech talent with global experience to sustain innovation and pipeline growth.
• Driving internationalization through strategic partnerships, licensing and cross-border commercialization.
• Transforming into a comprehensive pharmaceutical group to create a new development pattern in the industry.

• R&D acceleration - prioritize biologics and aesthetic product platforms, with focused investments in clinical development and CMC capabilities.
• Manufacturing scale-up - expand GMP-compliant capacity for both sterile biologics and medical-aesthetic devices/formulations.
• Commercial expansion - strengthen domestic specialty sales and progressively build international commercialization channels.
• Talent and governance - recruit senior global R&D and regulatory talent to accelerate filings in key markets.

• Capital allocation: shifting an increasing share of capex and R&D budget to biologics and medical-aesthetic platforms.
• Partnerships: executing licensing, co-development and distribution agreements to accelerate international reach.
• Infrastructure: building or upgrading GMP facilities and a centralized modern R&D center to shorten development timelines.
• Product mix: expanding higher-margin aesthetic products while stabilizing legacy prescription revenue streams for cash flow support.

Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK) - Vision Statement

• Integrity and responsibility as the foundation: Sihuan places ethical conduct, regulatory compliance and patient safety at the core of decision-making.
• Pragmatism and innovation: a focus on realistic, breakthrough-oriented research and development to translate science into accessible medicines.
• Cooperation and sharing: strategic partnerships, open collaboration with domestic and international institutions, and an emphasis on win‑win outcomes.
• Pursuit of excellence: continuous improvement in quality systems, manufacturing, clinical development and commercial execution.

• Organizational culture: employees are encouraged to be brave, cooperative, tolerant, passionate, diligent and pragmatic.
• Teamwork orientation: cross-functional collaboration between R&D, manufacturing and commercial teams to accelerate product launches and lifecycle management.
• Corporate social responsibility: commitment to public health programs, donations in emergency response, and product access initiatives.

• Integrity & responsibility: GMP-compliant manufacturing, pharmacovigilance systems and transparent reporting.
• Pragmatism & innovation: prioritization of high-unmet-need therapeutic areas and resource allocation to late-stage development to accelerate patient access.
• Cooperation & sharing: licensing, co-development and academic collaborations to leverage external expertise and expand the pipeline.
• Pursuit of excellence: quality metrics, continuous improvement programs and talent development to sustain operational excellence.